Equities research analysts expect AbbVie Inc. (NYSE:ABBV – Get Rating) to post earnings of $3.44 per share for the current quarter, Zacks reports. Four analysts have made estimates for AbbVie’s earnings, with the highest EPS estimate coming in at $3.52 and the lowest estimate coming in at $3.38. AbbVie reported earnings of $3.11 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 10.6%. The business is expected to announce its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that AbbVie will report full-year earnings of $14.03 per share for the current financial year, with EPS estimates ranging from $13.85 to $14.14. For the next financial year, analysts forecast that the firm will report earnings of $11.81 per share, with EPS estimates ranging from $11.25 to $12.30. Zacks’ earnings per share calculations are an average based on a survey of analysts that follow AbbVie.
AbbVie (NYSE:ABBV – Get Rating) last posted its quarterly earnings results on Friday, April 29th. The company reported $3.16 EPS for the quarter, beating the consensus estimate of $3.14 by $0.02. The firm had revenue of $13.36 billion during the quarter, compared to analysts’ expectations of $13.61 billion. AbbVie had a return on equity of 159.31% and a net margin of 22.00%. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.95 EPS.
AbbVie stock traded down $0.71 during trading hours on Thursday, hitting $151.72. The stock had a trading volume of 5,849,546 shares, compared to its average volume of 7,881,893. The company has a 50-day moving average of $158.15 and a two-hundred day moving average of $141.40. The company has a quick ratio of 0.71, a current ratio of 0.82 and a debt-to-equity ratio of 3.89. The company has a market cap of $268.11 billion, a PE ratio of 21.77, a price-to-earnings-growth ratio of 4.36 and a beta of 0.83. AbbVie has a fifty-two week low of $105.56 and a fifty-two week high of $175.91.
In other AbbVie news, Vice Chairman Robert A. Michael sold 43,105 shares of the stock in a transaction on Tuesday, March 1st. The stock was sold at an average price of $148.25, for a total value of $6,390,316.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jeffrey Ryan Stewart sold 27,690 shares of the stock in a transaction on Thursday, March 24th. The shares were sold at an average price of $159.20, for a total value of $4,408,248.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 488,383 shares of company stock worth $74,384,651. 0.08% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in ABBV. Castle Financial & Retirement Planning Associates Inc. bought a new position in AbbVie in the 4th quarter valued at $25,000. Intelligent Financial Strategies acquired a new position in shares of AbbVie in the 4th quarter valued at $27,000. Psagot Value Holdings Ltd. Israel lifted its stake in shares of AbbVie by 311.3% in the 4th quarter. Psagot Value Holdings Ltd. Israel now owns 4,360 shares of the company’s stock valued at $28,000 after purchasing an additional 3,300 shares during the period. Steward Financial Group LLC acquired a new position in shares of AbbVie in the 4th quarter valued at $30,000. Finally, GoalVest Advisory LLC acquired a new position in shares of AbbVie in the 1st quarter valued at $33,000. Hedge funds and other institutional investors own 67.03% of the company’s stock.
AbbVie Company Profile (Get Rating)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
- Get a free copy of the StockNews.com research report on AbbVie (ABBV)
- The Institutional Tide Has Turned For Cisco Systems
- Don’t Bet On Cheaper Oil, Not Yet Anway
- Can Nvidia Bounce Back
- A Reversal In The S&P 500 Is Confirmed
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.